Meera Patrawala1, Ying Cui2, Limin Peng2, Ramsay L Fuleihan3, Elizabeth K Garabedian4, Kiran Patel1, Lokesh Guglani5. 1. Department of Pediatrics, Division of Pulmonology, Allergy/Immunology, Cystic Fibrosis and Sleep, Emory University, 2015 Uppergate Drive, Atlanta, GA, 30322, USA. 2. Department of Biostatistics, Emory University, Atlanta, GA, USA. 3. Division of Allergy and Immunology, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 4. National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA. 5. Department of Pediatrics, Division of Pulmonology, Allergy/Immunology, Cystic Fibrosis and Sleep, Emory University, 2015 Uppergate Drive, Atlanta, GA, 30322, USA. lokesh.guglani@emory.edu.
Abstract
PURPOSE: Pulmonary manifestations are common in patients with primary immunodeficiency disorders (PIDs) but the prevalence, specific diseases, and their patterns are not well characterized. METHODS: We conducted a retrospective analysis of pulmonary diseases reported in the database of the United States Immunodeficiency Network (USIDNET), a program of the Immune Deficiency Foundation. PIDs were categorized into 10 groups and their demographics, pulmonary diagnoses and procedures, infections, prophylaxis regimens, and laboratory findings were analyzed. RESULTS: A total of 1937 patients with various PIDs (39.3% of total patients, 49.6% male, average age 37.9 years (SD = 22.4 years)) were noted to have a pulmonary disease comorbidity. Pulmonary diseases were categorized into broad categories: airway (86.8%), parenchymal (18.5%), pleural (4.6%), vascular (4.3%), and other (13.9%) disorders. Common variable immune deficiency (CVID) accounted for almost half of PIDs associated with airway, parenchymal, and other pulmonary disorders. Pulmonary procedures performed in 392 patients were mostly diagnostic (77.3%) or therapeutic (16.3%). These patients were receiving a wide variety of treatments, which included immunoglobulin replacement (82.1%), immunosuppressive (32.2%), anti-inflammatory (12.7%), biologic (9.3%), and cytokine (7.6%)-based therapies. Prophylactic therapy was being given with antibiotics (18.1%), antifungal (3.3%), and antiviral (2.2%) medications, and 7.1% of patients were on long-term oxygen therapy due to advanced lung disease. CONCLUSIONS: Pulmonary manifestations are common in individuals with PID, but long-term pulmonary outcomes are not well known in this group of patients. Further longitudinal follow-up will help to define long-term prognosis of respiratory comorbidities and optimal treatment modalities.
PURPOSE: Pulmonary manifestations are common in patients with primary immunodeficiency disorders (PIDs) but the prevalence, specific diseases, and their patterns are not well characterized. METHODS: We conducted a retrospective analysis of pulmonary diseases reported in the database of the United States Immunodeficiency Network (USIDNET), a program of the Immune Deficiency Foundation. PIDs were categorized into 10 groups and their demographics, pulmonary diagnoses and procedures, infections, prophylaxis regimens, and laboratory findings were analyzed. RESULTS: A total of 1937 patients with various PIDs (39.3% of total patients, 49.6% male, average age 37.9 years (SD = 22.4 years)) were noted to have a pulmonary disease comorbidity. Pulmonary diseases were categorized into broad categories: airway (86.8%), parenchymal (18.5%), pleural (4.6%), vascular (4.3%), and other (13.9%) disorders. Common variable immune deficiency (CVID) accounted for almost half of PIDs associated with airway, parenchymal, and other pulmonary disorders. Pulmonary procedures performed in 392 patients were mostly diagnostic (77.3%) or therapeutic (16.3%). These patients were receiving a wide variety of treatments, which included immunoglobulin replacement (82.1%), immunosuppressive (32.2%), anti-inflammatory (12.7%), biologic (9.3%), and cytokine (7.6%)-based therapies. Prophylactic therapy was being given with antibiotics (18.1%), antifungal (3.3%), and antiviral (2.2%) medications, and 7.1% of patients were on long-term oxygen therapy due to advanced lung disease. CONCLUSIONS: Pulmonary manifestations are common in individuals with PID, but long-term pulmonary outcomes are not well known in this group of patients. Further longitudinal follow-up will help to define long-term prognosis of respiratory comorbidities and optimal treatment modalities.
Authors: Yan Chen; Rob G Stirling; Eldho Paul; Fiona Hore-Lacy; Bruce R Thompson; Jo A Douglass Journal: J Allergy Clin Immunol Date: 2011-05-04 Impact factor: 10.793
Authors: A Stubbs; C Bangs; B Shillitoe; J D Edgar; S O Burns; M Thomas; H Alachkar; M Buckland; E McDermott; G Arumugakani; S Jolles; R Herriot; P D Arkwright Journal: Clin Exp Immunol Date: 2017-11-03 Impact factor: 4.330
Authors: John R Hurst; Nisha Verma; David Lowe; Helen E Baxendale; Stephen Jolles; Peter Kelleher; Hilary J Longhurst; Smita Y Patel; Elisabetta A Renzoni; Clare R Sander; Gerard R Avery; Judith L Babar; Matthew S Buckland; Siobhan Burns; William Egner; Mark M Gompels; Pavels Gordins; Jamanda A Haddock; Simon P Hart; Grant R Hayman; Richard Herriot; Rachel K Hoyles; Aarnoud P Huissoon; Joseph Jacob; Andrew G Nicholson; Doris M Rassl; Ravishankar B Sargur; Sinisa Savic; Suranjith L Seneviratne; Michael Sheaff; Prashantha M Vaitla; Gareth I Walters; Joanna L Whitehouse; Penny A Wright; Alison M Condliffe Journal: J Allergy Clin Immunol Pract Date: 2017-03-25
Authors: M Reisi; G Azizi; F Kiaee; F Masiha; R Shirzadi; T Momen; H Rafiemanesh; N Tavakolinia; M Modaresi; A Aghamohammadi Journal: Eur Ann Allergy Clin Immunol Date: 2017-05
Authors: S Jolles; S Sánchez-Ramón; I Quinti; P Soler-Palacín; C Agostini; B Florkin; L-J Couderc; N Brodszki; A Jones; H Longhurst; K Warnatz; F Haerynck; A Matucci; E de Vries Journal: Clin Exp Immunol Date: 2017-08-25 Impact factor: 4.330